Paratek Pharmaceuticals Announces Additional Funding Under the BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax
— Additional ~$19M Funding for Expanded Anthrax PEP Development Program — BARDA Contract Now Valued…
SeoulCeuticals Publishes First Official Layering Guide for Volufiline Snail Mucin Serum, Identifying Retinol Sequencing as the Cause of Preventable Irritation for Millions of Users